As Gleason score is a strong, independent predictor of adverse outcomes and we have a relatively young group of patients, it may require a longer follow-up time to observe a potential association between prostate cancer-specific death and TMPRSS2-ERG fusion type (translocation/deletion) or number (single/multiple). This evidence concerns the gene ERG and Familial prostate cancer.